Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1183/16000617.00001015 http://scihub22266oqcxt.onion/10.1183/16000617.00001015 26028639!9487825!26028639     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26028639&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26028639.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Eur+Respir+Rev 2015 ; 24 (136): 272-82 Nephropedia Template TP {{tp|p=26028639|t=2015. Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension |pdf=|usr=}}{{26028639}} gab.com Text Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension JO: Eur Respir Rev http://www.kidney.de/pget.php?&tw=1&pmid=26028639 #FOAvip Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but life-threatening disease resulting from unresolved thromboembolic obstructions. Pulmonary endarterectomy (PEA) surgery is the gold-standard treatment as it is potentially curative; however, not all patients are deemed operable and up to one-third have persistent or recurrent CTEPH after the procedure. Pulmonary arterial hypertension (PAH) and CTEPH have similar clinical presentations and histopathological features, so agents shown to be effective in PAH have often been prescribed to patients with CTEPH in the absence of proven therapies. However, clinical evidence for this strategy is not compelling. A number of small uncontrolled trials have investigated endothelin receptor antagonists, prostacyclin analogues and phosphodiesterase type 5 inhibitors in CTEPH with mixed results, and a phase III study of the endothelin receptor antagonist bosentan met only one of its two co-primary end-points. Recently, however, the soluble guanylate cyclase stimulator, riociguat, was approved in the USA and Europe for the treatment of inoperable or persistent/recurrent CTEPH following positive results from the phase III CHEST study (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Trial). This article reviews the current evidence for the use of pharmacological therapies in CTEPH. Twit Text FOAVip Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension ????Eur Respir Rev http://www.kidney.de/pget.php?&tw=1&pmid=26028639 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26028639 #FOAvip English Wikipedia <ref>{{Cite pmid|26028639}}</ref> Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension #MMPMID26028639 Hoeper MM Eur Respir Rev 2015[Jun]; 24 (136): 272-82 PMID26028639show ga Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but life-threatening disease resulting from unresolved thromboembolic obstructions. Pulmonary endarterectomy (PEA) surgery is the gold-standard treatment as it is potentially curative; however, not all patients are deemed operable and up to one-third have persistent or recurrent CTEPH after the procedure. Pulmonary arterial hypertension (PAH) and CTEPH have similar clinical presentations and histopathological features, so agents shown to be effective in PAH have often been prescribed to patients with CTEPH in the absence of proven therapies. However, clinical evidence for this strategy is not compelling. A number of small uncontrolled trials have investigated endothelin receptor antagonists, prostacyclin analogues and phosphodiesterase type 5 inhibitors in CTEPH with mixed results, and a phase III study of the endothelin receptor antagonist bosentan met only one of its two co-primary end-points. Recently, however, the soluble guanylate cyclase stimulator, riociguat, was approved in the USA and Europe for the treatment of inoperable or persistent/recurrent CTEPH following positive results from the phase III CHEST study (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Trial). This article reviews the current evidence for the use of pharmacological therapies in CTEPH. |Angioplasty, Balloon[MESH] |Antihypertensive Agents/adverse effects/*therapeutic use[MESH] |Arterial Pressure/*drug effects[MESH] |Chronic Disease[MESH] |Comorbidity[MESH] |Endarterectomy[MESH] |Humans[MESH] |Hypertension, Pulmonary/diagnosis/etiology/physiopathology/*surgery[MESH] |Patient Selection[MESH] |Predictive Value of Tests[MESH] |Pulmonary Artery/*drug effects/pathology/physiopathology[MESH] |Pulmonary Embolism/*complications/diagnosis/*drug therapy/physiopathology[MESH] |Risk Factors[MESH] |Treatment Outcome[MESH]Pharmacological therapy for patients with chronic thromboembolic pulmo(epmc).pdf DeepDyve Pubget Overpricing